Imunon Inc (IMNN) Q2 2024 Earnings Report

Imunon reported a Q2 2024 net loss of $4.788 million (-$0.51 per share) on total operating expenses of $5.013 million, reflecting the company’s ongoing clinical-stage burn and no revenue generation to date. Compared with Q2 2023, the net loss narrowed from $5.6 million (-$0.61 per share) as management pursued cost reductions and pipeline-focused spending. R&D expenses declined to $2.82 million (down from $3.10 million YoY), while G&A expense eased to $2.19 million (vs. $2.30 million YoY). The company ended the quarter with $5.31 million in cash and investments. Subsequent to quarter-end, Imunon announced a financing of approximately $9–10 million in net/gross proceeds, bringing cash and investments to roughly $14.5 million and extending cash runway into the third quarter of 2025. Management highlighted a strategic pivot around IMNN-001 in OVATION 2, reporting an 11.1-month improvement in overall survival in the intent-to-treat population and a hazard-ratio-driven ~35% OS improvement, underscoring the potential for a pivotal Phase 3 study in ovarian cancer. Management signaled readiness to pursue a Phase 2/Phase 3-aligned end-of-Phase 2 FDA meeting in the fall, with a target Phase 3 initiation in Q1 2025 and top-line data toward end-2028, contingent on capital access and patient recruitment. Separately, IMNN-101, a DNA vaccine candidate for seasonal COVID-19 boosters, is in Phase 1 with enrollment progressing; a partner search is expected upon Phase 1 readout by year-end. Overall, Imunon possesses a credible, data-driven growth narrative anchored by a potentially transformative ovarian cancer therapy, but remains heavily dependent on timely capital raises and successful Phase 3 execution to unlock meaningful value.